Lucentis was first approved in the US in 2007 ... as well as for Vabysmo (faricimab), a bispecific antibody that also provides less frequent dosing in wet AMD and DME.

It cites an “anticompetitive agreement” in the market for Lucentis active ingredient, the anti-VEGF antibody ranibizumab. Specifically, the ACGM claims that the companies entered into a ...

Antibody fragments have also been developed ... The products—ReoPro, Lucentis and Cimzia—are used as treatments for cardiovascular, ophthalmic and immunological indications, respectively ...

Background: To identify differences between Ranibizumab and Aflibercept in treatment-naïve patients with neovascular age-related macular degeneration (nvAMD) in a real-life clinical setting ...

Current therapies, such as ranibizumab (Lucentis; Genentech), target the ... intraocular administration of CCR3-specific neutralizing antibodies or a small-molecule inhibitor of CCR3 reduced ...